注释ID

981501641

变量_单倍型

NAT2*4, NAT2*5A, NAT2*5B, NAT2*6B, NAT2*7A

基因

NAT2

药物名称(英)

sulfapyridine

药物名称(中)

磺胺吡啶

PMID

19560446

类型

Metabolism/PK

含义

yes

记事

slow acetylators (two variant alleles) compared to (rapid acetylators *4/*4 - no variant alleles) and intermediate acetylators (one variant allele and one *4 allele). Variant alleles were defined as NAT2*5, *6, *7 (measured by T341C, C481T, G590A, A803G and G857A) therefore described here as *5A, *5B, *6B, *7A however exact genotypes not specified in paper. A single oral dose of sulfasalazine was given and pharmacokinetic parameters were measured at different times points. AUC N-acetylsulfapyradine/ AUC sulfapyradine was significantly different between all three phenotype groups.

专家论述

NAT2 *5A/*5A +*5A/*5B + *5A/*6B + *6B/*6B + *6B/*7A + *7A/*7A (assigned as slow acetylator phenotype) is associated with increased concentrations of sulfapyridine in healthy individuals as compared to NAT2 *4/*4.

等位基因

*5A/*5A +*5A/*5B + *5A/*6B + *6B/*6B + *6B/*7A + *7A/*7A

专家评论

备注

变体注释摘要

id	研究类型	特征类型
17842	cohort	Study Cohort